tbuckley/cabot-search huggingface dataset:
La méditation: après le bain (The Meditation: After the Bath)
Authors: M. Therese Southgate
Journal: JAMA (2006)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A double-blind evaluation of topical capsaicin in pruritic psoriasis
Authors: Charles N. Ellis, Brenda Berberian, Virginia I. Sulica, W. Alan Dodd, Michael T. Jarratt, H. Irving Katz, Steven Prawer, Gerald Krueger, Ira H. Rex, John E. Wolf
Journal: Journal of the American Academy of Dermatology (1993)
Evidence of CFTR Function in Cystic Fibrosis after Systemic Administration of 4-Phenylbutyrate
Authors: Pamela L. Zeitlin, Marie Diener-West, Ronald C. Rubenstein, Michael P. Boyle, Carlton K.K. Lee, Lois Brass-Ernst
Journal: Molecular Therapy (2002)

Most individuals with cystic fibrosis (CF) carry one or two mutations that result in a maturation defect of the full-length protein. One such mutation, ΔF508, results in a mutant membrane glycoprotein that fails to progress to the apical membrane, where the wild-type protein normally functions as a cyclic AMP-regulated chloride channel. 4-Phenylbutyrate (Buphenyl), an orally bioavailable short chain fatty acid, modulates heat shock protein expression and restores maturation of the ΔF508 protein in vitro and in vivo. We performed a randomized, double-blind, placebo-controlled, dose-escalation and safety study of Buphenyl in 19 adults with CF (homozygous ΔF508) to test the hypothesis that Buphenyl would be safe, well-tolerated, and associated with an increase in chloride transport in nasal epithelia. Three dose levels (20, 30, or 40 g divided t.i.d.) of drug or placebo were given for 1 week. Serial measurements of chloride transport by nasal potential difference (NPD) testing and metabolic safety testing were performed. A maximum tolerated dose of 20 g was defined based on minimal adverse reactions, the safety profile, and a statistically significant induction of chloride transport that was maximal by day 3. This short-term phase I/II study demonstrates proof of principle that modulation of ΔF508 CFTR biosynthesis and trafficking is a viable therapeutic approach for cystic fibrosis.
Digital ulcers predict a worse disease course in patients with systemic sclerosis
Authors: Carina Mihai, Robert Landewé, Désirée van der Heijde, Ulrich A Walker, Paul I Constantin, Ana Maria Gherghe, Ruxandra Ionescu, Simona Rednic, Yannick Allanore, Jérôme Avouac, László Czirják, Eric Hachulla, Gabriela Riemekasten, Franco Cozzi, Paolo Airò, Maurizio Cutolo, Ulf Mueller-Ladner, Marco Matucci-Cerinic
Journal: Annals of the Rheumatic Diseases (2015)

Objective Systemic sclerosis (SSc) is a systemic autoimmune disease with high morbidity and significant mortality. There is a great need of predictors that would allow risk stratification of patients with SSc and ultimately initiation of treatment early enough to ensure optimal clinical results. In this study, we evaluated whether a history of digital ulcers (HDU) at presentation may be a predictor of vascular outcomes and of overall clinical worsening and death in patients with SSc. Methods Patients from the EULAR Scleroderma Trials and Research (EUSTAR) database, satisfying at inclusion the 1980 American College of Rheumatology classification criteria for SSc, who had a follow-up of at least 3 years since baseline or who have died, were included in the analysis. HDU at presentation as a predictor of disease worsening or death was evaluated by Cox proportional hazards regression analysis. Results 3196 patients matched the inclusion criteria (male sex 13.2%, 33.4% diffuse subset). At presentation, 1092/3196 patients had an HDU (34.1%). In multivariable analysis adjusting for age, gender and all parameters considered potentially significant, HDU was predictive for the presence of active digital ulcers (DUs) at prospective visits (HR (95% CI)): 2.41 (1.91 to 3.03), p&lt;0.001, for an elevated systolic pulmonary arterial pressure on heart ultrasound (US-PAPs):1.36 (1.03 to 1.80), p=0.032, for any cardiovascular event (new DUs, elevated US-PAPs or LV failure): 3.56 (2.26 to 5.62), p&lt;0.001, and for death (1.53 (1.16 to 2.02), p=0.003). Conclusions In patients with SSc, HDU at presentation predicts the occurrence of DUs at follow-up and is associated with cardiovascular worsening and decreased survival.
A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of Patients with Metastatic Melanoma
Authors: Thomas K. Eigentler, Benjamin Weide, Filippo de Braud, Gianluca Spitaleri, Antonella Romanini, Annette Pflugfelder, Reinerio González-Iglesias, Annaelisa Tasciotti, Leonardo Giovannoni, Kathrin Schwager, Valeria Lovato, Manuela Kaspar, Eveline Trachsel, Hans D. Menssen, Dario Neri, Claus Garbe
Journal: Clinical Cancer Research (2011)

Abstract Purpose: L19-IL2 is an immunocytokine composed of an antibody fragment specific to the EDB domain of fibronectin, a tumor angiogenesis marker, and of human interleukin-2 (IL2). L19-IL2 delivers IL2 to the tumor site exploiting the selective expression of EDB on newly formed blood vessels. Previously, the recommended dose of L19-IL2 monotherapy was defined as 22.5 million international units (Mio IU) IL2 equivalents. In this study, safety and clinical activity of L19-IL2 in combination with dacarbazine were assessed in patients with metastatic melanoma. Experimental Design: The first 10 studied patients received escalating doses of L19-IL2 on days 1, 3, and 5 in combination with 1 g/m2 of dacarbazine on day 1 of a 3-weekly therapy cycle. Subsequently, 22 patients received L19-IL2 at recommended dose plus dacarbazine. Up to six treatment cycles were given, followed by a maintenance regimen with biweekly L19-IL2. Results: The recommended dose of L19-IL2 in combination with dacarbazine was defined as 22.5 Mio IU. Toxicity was manageable and reversible, with no treatment-related deaths. Twenty-nine patients were evaluable for efficacy according to Response Evaluation Criteria in Solid Tumors (RECIST). In a centralized radiology analysis, eight of 29 (28%) patients achieved a RECIST-confirmed objective response, including a complete response still ongoing 21 months after treatment beginning. The 12-month survival rate and median overall survival of the recommended dose–treated patients (n = 26) were 61.5% and 14.1 months, respectively. Conclusions: The repeated administration of L19-IL2 in combination with dacarbazine is safe and shows encouraging signs of clinical activity in patients with metastatic melanoma. This combination therapy is currently evaluated in a randomized phase II trial with patients with metastatic melanoma. Clin Cancer Res; 17(24); 7732–42. ©2011 AACR.
Adverse Effects of Chemonucleolysis
Authors: I. Leonard Bernstein
Journal: JAMA (1983)

<h3>To the Editor.—</h3> The article about chemonucleolysis by Phil Gunby (1983; 249:1115) was accurate and informative. General availability of intradiscal therapy with chymopapain offers a worthwhile alternative to surgery for patients with recalcitrant symptoms and signs of the lumbar disk syndrome. Moreover, the splendid cooperative effort by the American Academy of Orthopaedic Surgeons (AAOS) and the American Association of Neurological Surgeons (AANS) in organizing supervised instructional courses of this technique will serve as a prototype of professional postgraduate education. Participants in these courses were also warned about the risks of anaphylactic reactions to chymopapain, one of a family of enzymes that are particularly prone to induce IgE-mediated sensitization in susceptible persons.<sup>1,2</sup>The generalized incidence of chymopapain-induced anaphylaxis in the hospital is 1%, or ten times higher than the risk of penicillin anaphylaxis in the hospital, as determined by prospective statistics of the Boston Collaborative Drug Surveillance Program.<sup>3</sup>The
Circulating tumor cell detection and transcriptomic profiles in early breast cancer patients
Authors: F. Reyal, F. Valet, P. de Cremoux, C. Mathiot, C. Decraene, B. Asselain, E. Brain, S. Delaloge, S. Giacchetti, M. Marty, J.Y. Pierga, F.C. Bidard
Journal: Annals of Oncology (2011)
Extracorporeal photopheresis in lung transplant:The initial experience in our hospital
Authors: Myriam Aguilar Pérez, Maria Teresa Lazaro Carrasco de la Fuente, Jose Luis Bueno Cabrera, Ana Morales de la Plaza, Rosalia Laporta Hernandez, Piedad Ussetti Gil
Journal: European Respiratory Journal (2014)

INTRODUCTION   Extracorporeal photopheresis(ECP)could be a helpful treatment to slow progression of Bronchiolitis Obliterans Syndrome(BOS)as a manifestation of chronic rejection(CR)in lung transplantation(LT).   OBJECTIVE   To describe our experience with ECP in LT patients with CR not responding to other treatments.   PATIENTS&METHODS   LT patients with CR,as a progressive fall in respiratory flows despite changes in immunosuppression therapy,corticosteroid bolus and thymoglobulin.  ECP is performed according to a protocol:2 sessions/week for the first month,2 sessions/2 weeks for 3 months,followed by 2 sessions/month.  FEV1 is measured every 2 sessions.  A response is considered positive when the FEV1 has stabilized and/or the FEV1 has decreased less than during the previous three months.   RESULTS   The study includes 9 patients.4 male(44.4%).Mean age 49.89±17.4 years.  3 patients were affected by cystic fibrosis,2 by usual interstitial pneumonia,2 by emphysema,1α-1-antitrypsin deficit and 1 with lymphangioleiomyomatosis as the underlying disease.  Mean time from LT is 2534±1524 days.  The mean pre-ECP FEV1 is 1218±354.   CONCLUSIONS   Photophoresis can be helpful in slowing the progression of CR.
Tensional homeostasis and the malignant phenotype
Authors: Matthew J. Paszek, Nastaran Zahir, Kandice R. Johnson, Johnathon N. Lakins, Gabriela I. Rozenberg, Amit Gefen, Cynthia A. Reinhart-King, Susan S. Margulies, Micah Dembo, David Boettiger, Daniel A. Hammer, Valerie M. Weaver
Journal: Cancer Cell (2005)
A Lack of Self-Consciousness in Autism
Authors: Motomi Toichi, Yoko Kamio, Takashi Okada, Morimitsu Sakihama, Eric A. Youngstrom, Robert L. Findling, Kokichi Yamamoto
Journal: American Journal of Psychiatry (2002)

This study investigated self-consciousness in autism.An incidental memory task was conducted on 18 adults with high-functioning autism and 18 normal comparison subjects. Three kinds of orienting questions (phonological, semantic, and self-referent, i.e., "Does the word describe you?") were asked about target words (adjectives for personality traits) in order to induce different types of processing. This was followed by an unexpected recognition test.While semantic processing resulted in better memory than phonological processing in both groups, self-referent processing yielded better memory performance than semantic processing in the comparison group but not in the autistic group.The results suggest deficits in self-consciousness in individuals with autism.
Parasitic infections of the lung: a guide for the respiratory physician
Authors: H. Kunst, D. Mack, O. M. Kon, A. K. Banerjee, P. Chiodini, A. Grant
Journal: Thorax (2010)

Parasitic infections of the lung occur worldwide among both immunocompetent and immunocompromised patients and may affect the respiratory system in a variety of ways. This review provides an update on the presenting symptoms, signs, investigation and management of diseases affecting the lung caused by protozoa, nematodes and trematodes. The clinical presentations and radiographic findings of several of these diseases may mimic tuberculosis and malignancy. It is important to consider parasitic infections in the differential diagnosis of such lung diseases. If identified early, most parasitic diseases that affect the lung are curable with medical or surgical treatments.
IMMUNOLOGICAL TOLERANCE
Authors: Andrew Shaw, Barbara Berko, Thomas G. Wegmann
Journal: The Journal of Experimental Medicine (1974)

Although most mouse strain combinations succumb to a lethal wasting disease when parabiosed across a strong histocompatibility (H-2) barrier, a high proportion of DBA mice parabiosed to DBA/C3H F(1) hybrids survive and appear healthy. DBA mice accept C3H skin grafts following parabiosis, and may therefore be considered operationally tolerant of C3H antigens. Nonetheless, spleen cells from long-term DBA and F(1) parabionts give normal and enhanced responses, respectively, to C3H antigens in mixed lymphocyte culture (MLC). This indicates that the tolerance mechanism can distinguish between MLC recognition reactivity and in vivo effector reactivity, and that the former can therefore exist in the absence of the latter.
Hyperuricaemia and Gout in the Mariana Islands
Authors: Thomas A. Burch, William M. O’Brien, Richard Need, Leonard T. Kurland
Journal: Annals of the Rheumatic Diseases (1966)

Fisher (1959) and Decker and Lane (1959), Decker (1962), and Decker, Lane and Reynolds (1962) called attention to the high prevalence of gout and hyperuricaemia in Filipinos, and Lennane, Rose, and Isdale (1960) pointed out the high frequency of gout in the Maori of New Zealand.This report describes two other ethnic groups from the Pacific both with high prevalences of hyperuricaemia and gout. Material and MethodsSerum samples were obtained on individuals aged 40 years and above during surveys for amyotrophic lateral sclerosis in the Mariana Islands of the Central Pacific by the National Institute of Neurological Diseases and Blindness.The samples cannot be considered entirely random since the completion rate for this phase of the survey was only about 50 per cent.The findings are probably representative, however, since the respondents were unselected in so far as their uric acid levels are concerned.The individuals came from the villages of Merizo and Umatic on Guam, and the islands of Saipan, Tinian, and Rota, all in the Marianas.A total of 390 samples were obtained, 335 on Chamorros who are the native inhabi- tants and 55 on Carolinians who migrated to the area within the past 100 years.In addition forty samples were obtained from Carolinians living on the island of Truk in the central Caroline Islands.The bloods were separated within 2 to 3 hours of collection, and the sera frozen until analysed.Uric acids were determined in duplicate using the enzymaticspectrophotometric method as described by Liddle, Seegmiller, and Laster (1959). ResultsThe mean uric acid values of the Chamorros were 6'23 mg. per cent. in the males and 5-10 mg. per
Cold-insoluble globulin (fibronectin) in connective tissues of adult human lung and in trophoblast basement membrane.
Authors: B A Bray
Journal: Journal of Clinical Investigation (1978)

Cold-insoluble globulin (CIG), which is immunochemically indistinguishable from the fibroblast surface protein known as large external transformation-sensitive glycoprotein and fibronectin, was detected immunologically in connective tissue fractions from adult human lung. The fractions tested were (a) intact parenchyma, (b) acidic structural glycoproteins (ASG) extracted from lung parenchyma with 0.3 M acetic acid, and (c) isolated alveolar basement membrane (ABM). For comparison with ABM, preparations of human glomerular basement membrane and human trophoblast basement membrane (TBM) were tested. CIG was not detected in glomerular basement membrane but was present in large amounts in TBM. The CIG antigen could be solubilized from the parenchyma and from ABM by collagenase digestion which indicates that CIG occurs in lung connective tissue in association with collagen. Fibrinogen antigenic determinants were present in the ASG fraction, but the question of whether CIG and fibrin(ogen) are associated in lung connective tissue requires further study. When CIG was quantified by electroimmunoassay, intact lung parenchyma contained approximately equal to 0.4% CIG, ASG contained 3-4.5% CIG, ABM contained 0.1-0.9% CIG and TBM contained 1.5%-7.2% Cg. the evidence suggests that CIG is a chemical constituent of lung connective tissue matrix where it may influence the function of alveoli.
<i>Neu</i>-Induced Retroviral Rat Mammary Carcinogenesis: A Novel Chemoprevention Model for Both Hormonally Responsive and Nonresponsive Mammary Carcinomas
Authors: Stephan Woditschka, Jill D. Haag, Jordy L. Waller, Dinelli M. Monson, Andrew A. Hitt, Heidi L. Brose, Rong Hu, Yun Zheng, Philip A. Watson, Kwanghee Kim, Mary J. Lindstrom, Bob Mau, Vernon E. Steele, Ronald A. Lubet, Michael N. Gould
Journal: Cancer Research (2006)

Abstract Clinically relevant animal models of mammary carcinogenesis are crucial for the development and evaluation of new breast cancer chemopreventive agents. The neu-induced retroviral rat mammary carcinogenesis model is based on the direct in situ transfer of the activated neu oncogene into the mammary epithelium using a replication-defective retroviral vector. The resulting mammary carcinomas in intact Wistar-Furth rats exhibit a mixed hormonal response in the same proportion as has been observed in women. In intact rats, ∼50% of mammary carcinomas can be prevented by tamoxifen treatment. In ovariectomized animals, the mammary carcinomas are hormonally nonresponsive and cannot be prevented by tamoxifen. We evaluated the efficacy of retinoic X receptor–selective retinoids (rexinoids) in this novel model of mammary carcinogenesis. The rexinoids LG100268 and bexarotene (LG1069, Targretin) were highly efficacious in the prevention of neu-induced mammary carcinomas. Dietary LG100268 at 100 mg/kg diet decreased tumor multiplicity by 32% (P = 0.0114) in intact rats and 50% (P &amp;lt; 0.0001) in ovariectomized rats. Bexarotene treatment at a dose of 250 mg/kg diet was associated with reductions in tumor multiplicity of 84% (P &amp;lt; 0.0001) and 86% (P &amp;lt; 0.0001) in intact and ovariectomized animals, respectively. In addition to tumor multiplicity, proliferation and apoptosis were modulated by bexarotene treatment independently of estrogen signaling. The neu-induced retroviral rat mammary carcinogenesis model represents a valuable addition to existing rodent chemoprevention models. The model is useful for assessing the efficacy of chemopreventive agents, specifically those compounds that target hormonally nonresponsive tumors. (Cancer Res 2006; 66(13): 6884-91)
Prostate Pathology of Genetically Engineered Mice: Definitions and Classification. The Consensus Report from the Bar Harbor Meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee
Authors: Scott B. Shappell, George V. Thomas, Richard L. Roberts, Ron Herbert, Michael M. Ittmann, Mark A. Rubin, Peter A. Humphrey, John P. Sundberg, Nora Rozengurt, Roberto Barrios, Jerrold M. Ward, Robert D. Cardiff
Journal: Cancer Research (2004)

Abstract The Pathological Classification of Prostate Lesions in Genetically Engineered Mice (GEM) is the result of a directive from the National Cancer Institute Mouse Models of Human Cancer Consortium Prostate Steering Committee to provide a hierarchical taxonomy of disorders of the mouse prostate to facilitate classification of existing and newly created mouse models and the translation to human prostate pathology. The proposed Bar Harbor Classification system is the culmination of three meetings and workshops attended by various members of the Prostate Pathology Committee of the Mouse Models of Human Cancer Consortium. A 2-day Pathology Workshop was held at The Jackson Laboratory in Bar Harbor, Maine, in October 2001, in which study sets of 93 slides from 22 GEM models were provided to individual panel members. The comparison of mouse and human prostate anatomy and disease demonstrates significant differences and considerable similarities that bear on the interpretation of the origin and natural history of their diseases. The recommended classification of mouse prostate pathology is hierarchical, and includes developmental, inflammatory, benign proliferative, and neoplastic disorders. Among the neoplastic disorders, preinvasive, microinvasive, and poorly differentiated neoplasms received the most attention. Specific criteria were recommended and will be discussed. Transitions between neoplastic states were of particular concern. Preinvasive neoplasias of the mouse prostate were recognized as focal, atypical, and progressive lesions. These lesions were designated as mouse prostatic intraepithelial neoplasia (mPIN). Some atypical lesions were identified in mouse models without evidence of progression to malignancy. The panel recommended that mPIN lesions not be given histological grades, but that mPIN be further classified as to the absence or presence of documented associated progression to invasive carcinoma. Criteria for recognizing microinvasion, for classification of invasive gland-forming adenocarcinomas, and for characterizing poorly differentiated tumors, including neuroendocrine carcinomas, were developed and are discussed. The uniform application of defined terminology is essential for correlating results between different laboratories and models. It is recommended that investigators use the Bar Harbor Classification system when characterizing new GEM models or when conducting experimental interventions that may alter the phenotype or natural history of lesion progression in existing models.